Every 8-K that Solid Biosciences Inc. (SLDB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SLDB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLDB filings page.
Solid Biosciences Inc. filed a prospectus supplement on August 6, 2026 under its universal shelf registration statement on Form S-3 (File No. 333-287325), covering the offer and sale of up to $200.0 million of common stock pursuant to an Amended and Restated Sales Agreement with Jefferies LLC.
This new supplement follows a prior prospectus supplement under a different Form S-3 that permitted up to $85.0 million of common stock sales; as of the new filing, the company has issued and sold shares for aggregate gross proceeds of approximately $85.0 million under that earlier capacity and will no longer use it for additional sales. A legal opinion from Wilmer Cutler Pickering Hale and Dorr LLP regarding the shares is filed as Exhibit 5.1, and offerings will be made only by means of the new prospectus supplement and base prospectus.
Solid Biosciences Inc. reported the results of its Annual Meeting of Stockholders. Shareholders approved an amendment to the Certificate of Incorporation to increase authorized common stock from 240,000,000 to 480,000,000 shares.
They elected three Class II directors, Clare Kahn, Adam Stone and Lynne Sullivan, to serve until the 2029 annual meeting. Stockholders also ratified, on an advisory basis, Ilan Ganot as a Class I director through the 2028 meeting and confirmed PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026.
In addition, shareholders approved a non-binding advisory vote on executive compensation. Most proposals received strong support, with the share increase amendment passing with 85,604,508 votes for, 893,360 against and 27,502 abstaining.
Solid Biosciences Inc. reported a technical change to its Board structure. Effective at 4:00 p.m. Eastern Time on April 10, 2026, director Ilan Ganot resigned from the Class III director group and was immediately reappointed as a Class I director.
This adjustment sets both Class I and Class III at three directors each and is described as being for the sole purpose of achieving an equal balance among the Board’s three classes. Mr. Ganot’s new Class I term will run until the 2028 Annual Meeting of Stockholders.
The company plans to ask stockholders at the 2026 Annual Meeting to ratify, on an advisory basis, Mr. Ganot’s appointment as a Class I Director, reflecting its corporate governance focus. His compensation arrangements remain unchanged, and he will not receive any additional compensation for this reclassification.
Solid Biosciences Inc. reported positive new interim results from its Phase 1/2 INSPIRE DUCHENNE trial of gene therapy SGT-003 in pediatric Duchenne muscular dystrophy. As of the February 23, 2026 cutoff, 40 participants had been dosed at 1E14 vg/kg, with SGT-003 generally well tolerated under a steroid-only prophylactic regimen.
Muscle biopsies in 20 participants at Day 90 and 3 at Day 360 showed robust microdystrophin expression, with mean western blot levels of 60% and 91% of normal and strong beta-sarcoglycan and nNOS localization. Serum biomarkers of muscle damage such as CK, ALT, AST and LDH showed 30–46% mean reductions at Day 90 and sustained improvements at Day 360, consistent with better muscle integrity.
The company also highlighted stabilization-to-improvement in cardiac systolic function by left ventricular ejection fraction, particularly in participants with low-normal baseline values. Solid Biosciences has reached FDA alignment on the randomized, double‑blind, placebo‑controlled Phase 3 IMPACT DUCHENNE trial and expects first dosing in the first quarter of 2026, with additional regulatory and clinical updates planned for mid‑2026, including discussions on a potential accelerated approval pathway for SGT-003.
Solid Biosciences Inc. entered into a private placement with institutional investors to sell 14,973,257 common shares at $5.61 per share and pre-funded warrants for 27,807,482 shares at $5.609 per warrant, for expected gross proceeds of about $240.0 million and net proceeds of about $226.8 million.
The company expects to report preliminary cash, cash equivalents and available-for-sale securities of roughly $187.9 million as of December 31, 2025, and believes its cash plus net placement proceeds can fund operations into the first half of 2028. Pre-funded warrants are immediately exercisable at $0.001 per share and are subject to beneficial ownership limits of 4.99% or 9.99%, up to a maximum of 19.99%. The company agreed to register the resale of all securities issued and to pay liquidated damages of 1.0% of each investor’s amount per 30-day period if specified registration deadlines are not met.
Solid Biosciences (SLDB) filed an 8‑K announcing positive interim clinical data and a corporate update for SGT‑003, its gene therapy for Duchenne muscular dystrophy. The Phase 1/2 INSPIRE DUCHENNE trial has dosed 23 participants across 15 sites, with dosing expected to reach 30 by early 2026.
At Day 90 (N=10, ages 5–10), mean microdystrophin expression was 58% by western blot and mass spectrometry, and 51% microdystrophin‑positive fibers by immunofluorescence. Strong correlations linked microdystrophin to restoration of DAPC components, including beta‑sarcoglycan (0.95) and nNOS activity (0.95). Biomarkers of muscle injury improved, with mean reductions at Day 90 in CK, ALT, AST and LDH, and further improvements observed in limited Day 360 data. Early cardiac monitoring showed LVEF trending into normal ranges at Day 180 (N=8) and cTnI reductions.
Safety was generally favorable with steroids alone for prophylaxis; one treatment‑related Grade 3 immune‑mediated myositis resolved after steroid treatment, and dosing continued. The company plans to meet the FDA in the first half of 2026 to discuss potential registrational pathways and has initiated the Phase 3 IMPACT DUCHENNE study outside the U.S., with approvals in Canada and Australia.